Novel non-narcotic analgesic for acute and chronic pain

PROJECT SUMMARYSouth Rampart Pharma (SRP) is an early clinical-stage company focused on developing SRP-001, a novel non-opioid designed to treat moderate-to-severe acute and chronic pain without the dose-limiting hepatotoxicity of acetaminophen and nephrotoxicity of NSAIDs, and the misuse and addictive potential of opioids. SRP-001 is currently in Phase 1 trials where interim data support the expectation of safety and acceptable bioavailability and pharmacokinetics. SRP is currently conducting a Series A round to fund a planned Phase 2 scheduled to begin in H2 2023.Further development of SRP-001 will require third-party investor support to deliver proof-of-concept efficacy data in a Phase 2 trial. This will be followed by a critical need to partner with a major pharmaceutical or consumer health company to complete pivotal Phase 3 trials and commercialization. Based on historical data for pain therapeutics trials, the estimated cost of a Phase 3 program is $150M—a figure that is not attainable without a strategic partnership. In this Commercial Readiness Project submitted to PAR-23-069 (HEAL Commercialization Readiness (CRP) Program: Embedded Entrepreneurs for Small Business in Pain Management), SRP proposes to hire a CFO at 50% effort to pursue an aggressive partner engagement plan to secure a partnership to support Phase 3 trials and commercialization.SRP proposes two aligned aims with the two required activities outlined by PAR-23-069: Aim 1. Hire a business development expert in a company leadership role at 50% effort.Expected Outcome:1. CFO hired for 50% effort by month 2 of the project. Aim 2. Execute a partnering plan.Expected Outcomes:1. Initial contact with 200-300 prospective investors and potential partners with a specific interest inpain and CNS innovation by the end of Year 1.2. Meetings with 50-75 interested prospects by the end of Year 1.3. Data room access granted to 20-30 prospects interested in further discussions.4. Additional meetings with the prospect’s broader team and negotiations with 10-15 prospectsthrough Year 2.5. Agreements secured with 2-5 lead investors, closing out Series A financing by Month 18, andsecuring a partnership agreement with a major pharmaceutical company by the end of Year 2.